---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-041886"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:49:30.371529+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Indaptus partners with BeiGene to test Decoy20 + tislelizumab combo in solid tumors

## Summary
- Clinical supply agreement with BeiGene Switzerland GmbH for anti-PD-1 antibody tislelizumab.
- Indaptus funds all study costs except BeiGene's product; BeiGene supplies tislelizumab.
- Plans to seek FDA approval and begin combination study in 2025 for advanced solid tumors.
- Decoy20 is Indaptus' novel immune-response-inducing candidate for cancer therapy.

## SEC filing metadata
- accession: 0001493152-24-041886
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315224041886/0001493152-24-041886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315224041886/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-041886
- JSON: https://secwatch.observer/filing/0001493152-24-041886.json
- Plain text: https://secwatch.observer/filing/0001493152-24-041886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.